Skip to content

A prospective, multicenter, single-arm, feasibility clinical trial of an implantable closed-loop neurostimulator system for the efficacy and safety of drug-refractory generalized epilepsy

A prospective, multicenter, single-arm, feasibility clinical trial of an implantable closed-loop neurostimulator system for the efficacy and safety of drug-refractory generalized epilepsy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091842
Enrollment
Unknown
Registered
2024-11-05
Start date
2024-11-06
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-refractory generalized epilepsy

Interventions

Treatment group:Stimulation on after 4weeks(D28±7) of implantation

Sponsors

Fudan University HuaShan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 20 Years

Inclusion criteria

Inclusion criteria: (1) Patients with drug-refractory generalized epilepsy; (2) Age = 8 years old and = 20 years old, gender is not limited; (3) seizures 3 or more times per month; (4) the subject and his or her family have a reasonable expectation that the subject will be able to keep a seizure diary alone or with the help of family members; (5) Voluntarily participate in this trial and sign a written informed consent form; (6) Preoperative evaluation through surgical treatment of epilepsy; (7) Not participating in other clinical trials within three months.

Exclusion criteria

Exclusion criteria: (1) Have received DBS implantation in the past; (2) Active implants such as pacemakers, defibrillators, cochlear implants, drug infusion pumps, other neurostimulators, etc., or passive implants that affect the stimulator system; If the patient already has an implantable vagus nerve stimulator (VNS) in his body, he or she can participate in this trial after turning off the VNS; (3) Patients with contraindications to neurosurgery and severe cardiovascular and cerebrovascular diseases; (4) Clinically significant or unstable medical condition (including alcohol and/or drug abuse) or progressive central nervous system disease; (5) Combined with serious abnormalities in liver and kidney function and other systemic diseases that seriously affect health; (6) Women who are pregnant or have the intention to become pregnant in the past year, or lactating women; (7) Subjects judged by the investigator to have poor compliance with the subject, or subjects who are not suitable to participate in clinical trials.

Design outcomes

Primary

MeasureTime frame
responders‘ rate (proportion of patients with a =50% duction of seizures from baseline in the epilepsy diary at the last visit);The median relative decrease of seizures recorded in the epilepsy diary at the last visit;The proportion of patients with a =50% duction of seizures from baseline in 24-hour HD-EEG at the last visit.;The median relative decrease of seizures in 24-hour HD-EEG at the last visit.;Wechsler Intelligence Scale (WISC) score ;

Countries

China

Contacts

Public ContactChen liang

Fudan University HuaShan Hospital

chenlianghs@126.com+86 133 1173 5889

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026